SILVER SPRING, Md. (AP) - A panel of advisers to the Food and Drug Administration overwhelmingly backed approval for a highly anticipated anti-obesity pill from Vivus Inc., a drug which the FDA previously rejected due
to safety concerns.
The FDA panel of outside physicians voted 20-2 in favor of the weight loss drug Qnexa, setting the stage for a potential comeback for a drug that has been plagued by side effects since it was first submitted to the
agency in 2010.
A majority of panelists ultimately backed the drug due to its impressive weight loss results, with most patients reporting nearly 10 percent weight loss.
But the group stressed the importance of confirming the drug's safety, particularly its effects the heart, by tracking patients in a large, follow-up study.
FDA's decision is expected in April.
- Your Health: Do Diet Pills Really Work?
- Medical Spotlight: Weight Loss Pills
- People Pills for Pets
- Morning After Pill, Soon Available Over-The-Counter
- Texas Coach Accused of Giving Student Morning After Pill
- Dangerous New Diet Gaining Popularity
- Two Men Force Way into Palatka Home, Take Money and Pills
- Deputies: Man Arrested After Stealing Oxycontin Pills At Gainesville Pharmacy
- Pill Bust in Marion County
- Crimes Against Seniors- Woman is Scammed for Her Prescription Pills